-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, a study from Singapore compared Pfizer/BioNTech's Comirnaty, Moderna's Spikevax, Kexing's CoronaVac (Kerlefu), and Sinopharm's BBIBP-CorV (Zhongai Kewei) after vaccination in the real world.
Among them, Comirnaty and Spikevax are mRNA vaccines, and Clarion and Zhongai Kewei are inactivated vaccines
Currently, about 96% of Singapore's population has been vaccinated against COVID-19
Based on the mRNA vaccine of Pfizer/BioNTech, the infection risk and severe risk after 2 doses of different new crown vaccines are shown in the figure
The researchers said that assuming two doses of Comirnaty had a protection rate of 90% against severe COVID-19 cases, the protection rates of Spikevax, Clarifex, and Zhongai Kewei were 96%, 54%, and 84%, respectively
Attached:
Note: The original text has been deleted
(Related research sources: https://academic.